MedTrace Logo

A Study to Evaluate P-Glucose, Safety and Tolerability After Oral Single Dosing of AZD6370 in Type 2 Diabetic Patients

NCT00690287 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2012-01-11

No results posted yet for this study

Summary

The purpose of this study is to assess the effect of AZD6370 on blood sugar and to study safety and tolerability in patients with type 2 diabetes.

Conditions

Interventions

DRUG

AZD6370

Oral single doses a+b+c, o.d., suspension

DRUG

AZD6370

Oral single dose, o.d., b.i.d. and q.i.d., suspension

DRUG

Placebo

Placebo

Sponsors & Collaborators

Principal Investigators

  • Klas Malmberg, MD, PhD, Prof. · AstraZeneca R&D Mölndal, SE-431 83 Mölndal, Sweden

  • Wolfgang Kühn, MD · Quintiles AB, Phase I Services, Strandbodgatan 1, SE-753 23 Uppsala, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00690287 on ClinicalTrials.gov